Chemomab Therapeutics (NASDAQ:CMMB) Trading 0.7% Higher – What’s Next?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) shares traded up 0.7% on Friday . The company traded as high as $2.79 and last traded at $2.72. 165,423 shares traded hands during mid-day trading, an increase of 29% from the average session volume of 128,348 shares. The stock had previously closed at $2.70.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Saturday, September 27th. Oppenheimer increased their price objective on Chemomab Therapeutics from $10.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $26.50.

Chemomab Therapeutics Trading Up 0.7%

The business has a 50-day moving average price of $3.30 and a 200 day moving average price of $4.31. The company has a market cap of $14.06 million, a price-to-earnings ratio of -1.15 and a beta of 0.57.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its earnings results on Thursday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.44. On average, analysts anticipate that Chemomab Therapeutics Ltd. Sponsored ADR will post -1 earnings per share for the current year.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently raised its position in Chemomab Therapeutics stock. Virtu Financial LLC lifted its stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,803 shares of the company’s stock after acquiring an additional 16,358 shares during the quarter. Virtu Financial LLC owned approximately 0.21% of Chemomab Therapeutics worth $34,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).